Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 6
1991 2
1992 2
1993 1
1994 3
1995 2
1996 2
1997 5
1999 6
2000 2
2001 4
2002 5
2003 7
2004 3
2005 6
2006 3
2007 5
2008 4
2009 1
2010 1
2011 2
2012 1
2013 5
2014 4
2015 7
2016 10
2017 5
2018 3
2019 5
2020 5
2021 5
2022 6
2023 6

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
Methylxanthines and ryanodine receptor channels.
Guerreiro S, Marien M, Michel PP. Guerreiro S, et al. Among authors: michel pp. Handb Exp Pharmacol. 2011;(200):135-50. doi: 10.1007/978-3-642-13443-2_5. Handb Exp Pharmacol. 2011. PMID: 20859795 Review.
[Parkinson disease: mechanisms of cell death].
Michel PP, Hirsch EC, Agid Y. Michel PP, et al. Rev Neurol (Paris). 2002 Dec;158 Spec no 1:S24-32. Rev Neurol (Paris). 2002. PMID: 12690661 Review. French.
Levodopa in the treatment of Parkinson's disease: a consensus meeting.
Agid Y, Ahlskog E, Albanese A, Calne D, Chase T, De Yebenes J, Factor S, Fahn S, Gershanik O, Goetz C, Koller W, Kurth M, Lang A, Lees A, Lewitt P, Marsden D, Melamed E, Michel PP, Mizuno Y, Obeso J, Oertel W, Olanow W, Poewe W, Pollak P, Tolosa E, et al. Agid Y, et al. Among authors: michel pp. Mov Disord. 1999 Nov;14(6):911-3. doi: 10.1002/1531-8257(199911)14:6<911::aid-mds1001>;2-h. Mov Disord. 1999. PMID: 10584663 Review. No abstract available.
Levodopa in the treatment of Parkinson's disease: current controversies.
Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F. Olanow CW, et al. Among authors: michel pp. Mov Disord. 2004 Sep;19(9):997-1005. doi: 10.1002/mds.20243. Mov Disord. 2004. PMID: 15372588 Review.
Neuroprotective and neurorestorative potential of xenon.
Lavaur J, Lemaire M, Pype J, Le Nogue D, Hirsch EC, Michel PP. Lavaur J, et al. Among authors: michel pp. Cell Death Dis. 2016 Apr 7;7(4):e2182. doi: 10.1038/cddis.2016.86. Cell Death Dis. 2016. PMID: 27054337 Free PMC article. No abstract available.
124 results